Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Coagulation Factor VIIa variant
BIOLOGICAL
2 trials
Sponsors
Catalyst Biosciences
Conditions
Factor VII Deficiency
Glanzmann Thrombasthenia
Hemophilia A With Inhibitor
Hemophilia B With Inhibitor
Phase 1
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
Terminated
NCT04548791
Catalyst Biosciences
Factor VII Deficiency, Glanzmann Thrombasthenia, Hemophilia A With Inhibitor
Start: 2021-05-17
End: 2021-12-03
Updated: 2021-12-21
Phase 2
Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B
Completed
NCT03407651
Catalyst Biosciences
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Start: 2017-12-18
End: 2019-04-13
Updated: 2021-09-23
Related Papers
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety.
2021-08-17
13 citations
Opportunities for Improvement: The Lot of the Inhibitor Patient Is Not a Happy One
Blood
2018-11-29